Peter Griffith

Peter Griffith inquired about any displacement ServiceTitan has seen on the commercial side, the reasons for winning against competitors, and the initial products landed with commercial deals.

Answer

Co-Founder and President Vahe Kuzoyan attributed ServiceTitan's increased traction in commercial to the improved quality of the product, especially on the construction side, and a successful track record of taking large enterprise customers live, which is challenging in this space.

Peter Griffith, on for Tyler Radke, asked about the typical product adoption pathway within the clinical suite for a customer after they have adopted EDC.

Answer

CEO Peter Gassner explained that adoption varies by customer. EDC and the clinical database (CDB) often go together. Success with EDC is a good indicator for future eCOA adoption, as those areas are closely related. However, he noted that other products like RTSM, Study Training, and Site Connect are more influenced by the adoption of eTMF and CTMS, not necessarily EDC.

Peter Griffith, on for Tyler Radke, asked about the timeline for achieving cross-selling success with EvolutionIQ, given only one overlapping customer, and if any changes to the selling motion are needed.

Answer

CEO Githesh Ramamurthy responded that the primary growth for EvolutionIQ is in its core markets of disability and workers' comp. He clarified that the main synergy is a product-level integration, where EvolutionIQ's medical summarization capability will be added to CCCS's Casualty solution suite and then sold by the traditional CCCS sales team. The single customer overlap is not the main focus of the synergy strategy.